HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ikuo Hagino Richard A. Jonas Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anttila, V. Articles by Jonas, R. A. Search for Related Content PubMed PubMed Citation Articles by Anttila, V. Articles by Jonas, R. A. Related Collections Extracorporeal circulation

J Thorac Cardiovasc Surg 2006;132:948-953
© 2006 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Aprotinin improves cerebral protection: Evidence from a survival porcine model

^a Department of Cardiovascular Surgery, Children's Hospital Boston, Harvard Medical School, Boston, Mass
^b Department of Biostatistics, Children's Hospital Boston, Harvard Medical School, Boston, Mass
^c Department of Pathology, Children's Hospital Boston, Harvard Medical School, Boston, Mass
^d Department of Surgery, University Hospital of Oulu, Oulu, Finland
^e Department of Cardiovascular Surgery, Children's National Medical Center, Washington, DC.

Received for publication August 16, 2005; revisions received January 26, 2006; accepted for publication June 13, 2006.

^_* Address for reprints: Richard A. Jonas, MD, Department of Cardiovascular Surgery, Children's National Medical Center, 111 Michigan Ave, Washington, DC 20010. (Email: rjonas{at}cnmc.org).

Objective: Aprotinin is a serine protease inhibitor used during cardiac surgery to reduce blood loss and preserve platelet function. It has also been shown to reduce leukocyte activation during and after cardiopulmonary bypass. The goal of the study was to test the hypothesis that aprotinin could reduce cerebral injury after low-flow cardiopulmonary bypass and deep hypothermic circulatory arrest.

Methods: Sixteen piglets (mean weight, 13.6 ± 1.3 kg) were randomly assigned to receive aprotinin or placebo (8 animals per group) before a 120-minute period of deep hypothermic circulatory arrest (15°C) or 25 mL · kg^–1 · min^–1 low-flow cardiopulmonary bypass (25°C or 34°C). Piglets had a cranial window placed over the parietal cerebral cortex for direct examination of the microcirculation by means of intravital microscopy. Rhodamine-stained leukocytes were observed in postcapillary venules, with analysis for adhesion and rolling. Plasma was labeled with fluorescein isothiocyanate–dextran for assessment of functional capillary density. Neurologic and histologic scores were used as the primary outcome measures.

Results: During rewarming, the mean number of both rolling and adherent leukocytes was significantly lower after aprotinin administration (P < .05). At 5 and 15 minutes of rewarming, functional capillary density recovered faster with aprotinin treatment (P < .05). Functional outcome (neurologic deficit score) on postoperative day 1 was significantly improved in aprotinin-treated piglets (P < .05).

Conclusions: Aprotinin reduces inflammation and improves neurologic outcome after a prolonged period of deep hypothermic circulatory arrest or low-flow cardiopulmonary bypass.

This article has been cited by other articles:

				Y. Iwata, T. Okamura, N. Ishibashi, D. Zurakowski, H. G.W. Lidov, and R. A. Jonas Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1521 - 1529. [Abstract] [Full Text] [PDF]

				R. C. Landis Redefining the Systemic Inflammatory Response Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2009; 13(2): 87 - 94. [Abstract] [PDF]

				N Ishibashi, Y Iwata, D Zurakowski, H. Lidov, and R. Jonas Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass Perfusion, March 1, 2009; 24(2): 99 - 105. [Abstract] [PDF]

				T Okamura, N Ishibashi, Y Iwata, D Zurakowski, and R. Jonas Aprotinin concentration varies significantly according to cardiopulmonary bypass conditions Perfusion, November 1, 2008; 23(6): 355 - 360. [Abstract] [PDF]

				B.J. Evans, D.O. Haskard, J.R. Finch, I.R. Hambleton, R.C. Landis, and K.M. Taylor The inflammatory effect of cardiopulmonary bypass on leukocyte extravasation in vivo. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 999 - 1006. [Abstract] [Full Text] [PDF]

				Y. Iwata, O. Nicole, T. Okamura, D. Zurakowski, and R. A. Jonas Aprotinin confers neuroprotection by reducing excitotoxic cell death J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 573 - 578. [Abstract] [Full Text] [PDF]

				M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]